报价延迟最少15分钟:2025/07/20 13:12 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.94 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.12/-1.15
|
|
企业价值
401.91M
|
| 资产负债 |
|
每股账面净值
4.47
|
| 现金流量 |
|
现金流量率
0.07
|
| 损益表 |
|
收益
75.62M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:12 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
